46. Yupelri

Theravance logo

Active ingredient: revefenacin 
Disease: chronic obstructive pulmonary disorder
Peak sales estimate: $250 million 
Approved: Nov. 8 
Company: Mylan and Theravance 

The scoop: In November, Theravance and Mylan’s Yupelri became the first once-daily, nebulized bronchodilator for chronic obstructive pulmonary disorder (COPD). But the long-acting muscarinic antagonist (LAMA) will face an uphill battle in a crowded COPD market, according to Brian Skorney, an analyst at Baird Equity Research, who predicted its peak sales to exceed $250 million in 2030. “We think the opportunity for a nebulized LAMA is relatively limited by the treatment paradigm in COPD, where combination therapy is the mainstay and there is wide availability of numerous inhalers containing two-three mechanisms in one,” he wrote in a note. But this won’t be the first hurdle for revefenacin—GlaxoSmithKline acquired the rights to the drug back in 2004, but dumped it after finding its formulation was not compatible with the company’s proprietary inhaler. — Amirah Al Idrus

46. Yupelri

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.